Pipeline

Overview

The drug pipeline of Priavoid is composed of 7 development programs for 6 CNS diseases:

  • Alzheimer’s disease
  • Neuropathic pain
  • Amyotrophic lateral sclerosis
  • Tauopathies
  • Huntington’s disease
  • Parkinson’s disease

PRI-002

PRI-002

is the most advanced drug in our pipeline for the causal treatment of Alzheimer’s disease (AD).

 

Thus, PRI-002 has three unique selling propositions (USPs):

 

New mechanism of action
Specific elimination of toxic Aβ oligomers

New drug substance class
Synthetic all-D-peptide

Oral drug administration
Protease resistant

Intervention Strategy

Intervention Strategy

Priavoid developed a completely new therapeutic strategy for the causal treatment of Alzheimer’s disease.  The orally available D-peptide PRI-002  permeates the blood-brain barrier effectively, does not interfere with formation or clearance of non-toxic Aß monomers, but specifically eliminates cytotoxic  Aß-oligomers.

 

Partnering

Partnering is a key component of Priavoids strategy